Throughout the body, the vasculature and the nervous system are fellow travelers. Renaissance physician and anatomist Andreas Vesalius described their proximity on the macroanatomical level in the 16th century, and modern microscopic techniques have shown that it extends into the micrometer range – where there is a blood vessel, there is often a nerve nearby, and vice versa.
Human lipoprotein(a) (Lp(a)) is a lipoprotein complex composed of a low-density lipoprotein (LDL) particle and a large highly polymorphic glycoprotein named apolipoprotein (a) (apo(a)). There is evidence that Lp(a) is linked to cardiovascular disorder risk.
Under pathologic conditions such as vascular injury or atherosclerosis, the hyperactivation of platelets may lead to occlusive thrombus formation, myocardial infarction or stroke. Although there are several targets for clot prevention validated clinically, these strategies may present bleeding risk as a limitation. Researchers from the University of Michigan have reported on CS-014, a histone deacetylase (HDAC) inhibitor aimed to reduce clot formation without risk of bleeding.
Heterozygous familial hypercholesterolemia (HeFH) patients treated with lerodalcibep achieved a 58.6% reduction in LDL-cholesterol at week 24 and a 65% reduction at the mean of weeks 22 and 24 in the phase III trial Liberate-HeFH. The developer, Cincinnati-based Lib Therapeutics Inc., was founded in 2015 when it licensed the technology from Bristol Myers Squibb Co. but is just now emerging from stealth.
The U.S. FDA has given Aquedeon Medical Inc. the green light to conduct an IDE clinical trial of its Duett vascular graft system. The device is designed to improve outcomes in surgical thoracic aortic procedures by simplifying treatment of target vessels and reducing overall procedure time.
Both oxidative stress and inflammation are the main hallmarks in the development of heart failure. Researchers from the Hefei University of Technology have reported on the discovery and optimization of a series of pterostilbene derivatives intended to be used in heart failure.
Merck & Co. Inc. is pledging major resources on its prospect in the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor space with a phase III program that together will enroll about 17,000 subjects and test oral peptide MK-0616’s effect on tackling low-density lipoprotein cholesterol.
Dublin-based Medtronic plc. has invested considerable resources into its renal denervation program, but the company has not completed its regulatory journey for the U.S. market just yet. Medtronic failed to persuade an FDA advisory committee of the virtues of its Symplicity Spyral device due to inconsistent results from the two major studies presented at the hearing but vowed to keep working on the application despite the sustained headwinds.
Eli Lilly & Co. has described pyrrolidine compounds targeting apolipoprotein(a) (Apo[a]) and acting as lipoprotein(a)-lowering agents reported to be useful for the treatment of cardiovascular disorders.
Obesity is known to be associated with metabolic and cardiovascular disorders such as insulin resistance, type 2 diabetes, hypertension, or heart failure, all presenting a chronic low-grade inflammatory component. The activation of the NLRP3 inflammasome pathway appears to be linked to the development of cardio-metabolic diseases.
RSS
